Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives $20.40 Consensus Price Target from Brokerages

Telix Pharmaceuticals Limited (NASDAQ:TLX) has received an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $20.40.

A number of equities research analysts recently weighed in on the stock. Wedbush reaffirmed an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Royal Bank Of Canada lowered Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research report on Friday, July 17th. Citigroup reissued a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a report on Wednesday, September 2nd. Finally, Weiss Ratings upgraded Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, August 21st.

Telix Pharmaceuticals Stock Performance

NASDAQ TLX opened at $12.34 on Thursday. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.85 and a current ratio of 2.01. Telix Pharmaceuticals has a fifty-two week low of $6.28 and a fifty-two week high of $12.48. The business has a 50 day moving average price of $11.24 and a two-hundred day moving average price of $10.10.

Hedge Funds Weigh In On Telix Pharmaceuticals

Large investors have recently modified their holdings of the stock. Rhumbline Advisers grew its position in shares of Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after acquiring an additional 1,392 shares in the last quarter. Bank of America Corp DE lifted its position in Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after purchasing an additional 8,423 shares during the period. XTX Topco Ltd acquired a new position in Telix Pharmaceuticals during the fourth quarter worth about $89,000. XY Capital Ltd bought a new position in shares of Telix Pharmaceuticals during the 1st quarter valued at about $120,000. Finally, IHT Wealth Management LLC acquired a new position in shares of Telix Pharmaceuticals in the 2nd quarter worth approximately $213,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.